HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Physiological genomics of antidepressant targets: keeping the periphery in mind.

Abstract
The plasma membrane transporters that clear extracellular serotonin (5-HT) and norepinephrine (NE), serotonin transporters (SERTs) and NE transporters (NETs), have received considerable attention over the past four decades because of their roles in amine neurotransmitter inactivation. In addition, they interact with many centrally active drugs, including multiple classes of antidepressants such as the serotonin-selective reuptake inhibitors, typified by fluoxetine (Prozac), and the more recently developed norepinephrine-selective transporter antagonists, such as reboxetine. The therapeutic utility of these agents supports biogenic amine theories of affective disorders and raises the question as to whether SERT and NET exhibit a functional genetic variation that could influence risk for behavioral disorders. Although evidence exists that a promoter polymorphism in SERT may influence behavioral states, this contention is not without complexity and its mechanism of action remains poorly understood. The identification of coding variants of NETs and SERTs would offer important opportunities to connect genotype to phenotype. However, given the limited frequency of transporter coding variations evident to date in general population surveys or in psychiatric genetic studies, the identification of informative functional variants of transporters will likely require refined phenotypes. In this regard, NET and SERT play critical roles in cardiovascular and gastrointestinal physiology, respectively. This perspective reviews recent human and mouse studies that suggest how peripheral autonomic phenotypes, linked to genetic disruption of NET and SERT function, can aid in the phenotypic segregation needed for advanced theories of biogenic amine dysfunction and pharmacogenetics.
AuthorsR D Blakely
JournalThe Journal of neuroscience : the official journal of the Society for Neuroscience (J Neurosci) Vol. 21 Issue 21 Pg. 8319-23 (Nov 01 2001) ISSN: 1529-2401 [Electronic] United States
PMID11606618 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Antidepressive Agents
  • Carrier Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Neurotransmitter Agents
  • Norepinephrine Plasma Membrane Transport Proteins
  • SLC6A2 protein, human
  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins
  • Symporters
Topics
  • Antidepressive Agents (metabolism)
  • Carrier Proteins (genetics, metabolism)
  • Genetic Variation
  • Genomics
  • Genotype
  • Humans
  • Membrane Glycoproteins (genetics, metabolism)
  • Membrane Transport Proteins
  • Mental Disorders (genetics, metabolism)
  • Nerve Tissue Proteins
  • Neurotransmitter Agents (metabolism)
  • Norepinephrine Plasma Membrane Transport Proteins
  • Peripheral Nervous System (metabolism)
  • Phenotype
  • Polymorphism, Genetic
  • Serotonin Plasma Membrane Transport Proteins
  • Symporters (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: